Peptide Market Surges Beyond GLP-1s, Sparking Debate Over Access

The market for peptides is experiencing a significant surge beyond GLP-1s, leading to a 'Wild West' scenario and creating tension between compounding pharmacies and commercial drug companies over patient access, with the FDA under pressure to address the issue.